Seronegative fibrosing cholestatic hepatitis С after liver retransplantation for unresectable neuroendocrine tumor liver metastases

We present an uncommon case of liver graft dysfunction caused by seronegative hepatitis C-related fibrosing cholestatic hepatitis after cadaver liver transplantation for unresectable liver metastases of neuroendocrine small intestine cancer followed by living relation donor liver fragment retransplantation for primary graft nonfunction. Early postoperative period was complicated by hepatic artery thrombosis, cerebral hemorrhage, acute cellular rejection, bilateral polysegmental pneumonia, bleeding into neck soft tissues, severe surgical site infection, and sepsis. Anticoagulant therapy, as well as the absence of Hepatitis C Virus antibodies made difficult early diagnostics of fibrosing cholestatic hepatitis. A present-day antiviral therapy produced a complete clinical and virological response. At control examination performed at 240 days after surgery, there were neither signs of cancer progression no graft dysfunction. Liver transplantation in that case was an example of radical and effective treatment method for unresectable liver metastases of neuroendocrine small intestine cancer. Timely diagnosis and proper treatment of fibrosing cholestatic hepatitis made it possible to save the liver graft and patient's life.

1. Frilling A, Modlin IM, Kidd M, Russell C, Breitenstein S, Salem R, et al. Recommendations for management of patients with neuroendocrine liver metastases. Lancet Oncol. 2014;15(1):e8– 21. PMID: 24384494 https://doi.org/10.1016/S1470-2045(13)70362-0

2. Ierardi AM, Biondetti P, Padovano B, Magenta Biasina A, Bongini M, Carrafiello G. Intra-caval percutaneous radiofrequency ablation for a neuroendocrine tumor (NET) metastasis in transplanted liver. Cardiovasc Intervent Radiol. 2018;41(12):1962– 1967. PMID: 30014252 https://doi.org/10.1177/1179551419884058

3. Hofland J, Kaltsas G, De Herder WW. Advances in the diagnosis and management of well-differentiated neuroendocrine neoplasms. Endocr Rev. 2020;41(2):371–403. PMID: 31555796 https://doi.org/10.1210/endrev/bnz004

4. Zhang Y, Shang L, Zhang PP, Chen L-H, Wang W, Fang C, et al. Clinicopathological features and prognostic validity of the European neuroendocrine tumor society (ENETS) and American joint committee on cancer (AJCC) 8th staging systems in colonic neuroendocrine neoplasms. Cancer Med. 2019;8(11):5000–5011. PMID: 31293053 https://doi.org/10.1002/cam4.2370

5. Fan ST, Le Treut YP, Mazzaferro V, Burroughs AK, Olausson M, Breitenstein S, et al. Liver transplantation for neuroendocrine tumour liver metastases. HPB (Oxford). 2015;17(1):23–28. PMID: 24992381 https://doi.org/10.1111/hpb.12308

6. Nigri G, Petrucciani N, Debs T, Mangogna LM, Crovetto A, Moschetta G, et al. Treatment options for PNET liver metastases: a systematic review. World J Surg Oncol. 2018;16(1):142. PMID: 30007406 https://doi.org/10.1186/s12957-018-1446-y

7. Мальцева А.П., Сюткин В.Е., Колышев И.Ю., Рудаков В.С., Светлакова Д.С., Садыхов З.А. и др. Трансплантация в онкологии – будущее мультидисциплинарного подхода. Трансплантология. 2019;11(3):218–233. Maltseva AP, Syutkin VE, Kolyshev IYu, Rudakov VS, Svetlakova DS, Sadykhov ZA, et al. Transplantation in oncology: the future of a multidisciplinary approach. Transplantologiya. The Russian Journal of Transplantation. 2019;11(3):218–233. (In Russ.). https://doi.org/10.23873/2074-0506-2019-11-3-218-233

8. Wang R, Zheng-Pywell R, Chen HA, Bibb JA, Chen H, Rose JB. Management of gastrointestinal neuroendocrine tumors. Clin Med Insights Endocrinol Diabetes. 2019;12:1179551419884058. eCollection 2019. PMID: 31695546 https://doi.org/10.1177/1179551419884058

9. Артемьев А.И., Найденов Е.В., Забежинский Д.А., Губарев К.К., Колышев И.Ю., Рудаков В.С. и др. Трансплантация печени при нерезектабельном альвеококкозе печени. Современные технологии в медицине. 2017;9(1):123–128. Artemev AI, Naydenov EV, Zabezhinskiy DA, Gubarev KK, Kolyshev IYu, Rudakov VS, et al. Liver transplantation for unresectable hepatic alveolar echinococcosis. Sovremennye tehnologii v medicine = Modern Technologies in Medicine. 2017;9(1):123–128. (In Russ.). http://doi.org/10.17691/stm2017.9.1.16

10. Новрузбеков М.С., Олисов О.Д. Сосудистые осложнения после ортотопической трансплантации печени. Трансплантология. 2017;9(1):35–50. Novruzbekov MS, Olisov OD. Vascular complications after orthotopic liver transplantation. Transplantologiya. The Russian Journal of Transplantation. 2017;9(1):35–50. (In Russ.). https://doi.org/10.23873/2074-0506-2017-9-1-35-50

11. Tan-Tam C, Segedi M, Buczkowski A, Hussaini T, Yoshida EM, Chung S, et al. Surgical complications of liver transplantation. AME Med J. 2018;3:107. https://doi.org/10.21037/amj.2018.10.02

12. Hernandez Del PM, Martin P, Simkins J. Infectious complications after liver transplantation. Gastroenterol Hepatol (NY). 2015;11(11):741–753. PMID: 27134589

13. Восканян С.Э., Артемьев А.И., Сушков А.И., Колышев И.Ю., Рудаков В.С., Шабалин М.В. и др. Особенности сосудистых реконструкций и результаты 220 родственных трансплантаций правой доли печени взрослым пациентам. Альманах клинической медицины. 2018;46(6):598–608. Voskanyan SE, Artemev AI, Sushkov AI, Kolyshev IYu, Rudakov VS, Shabalin MV, et al. Vascular reconstruction and outcomes of 220 adult-to-adult right lobe living donor liver transplantations. Almanac of Clinical Medicine. 2018;46(6):598–608. (In Russ.). https://doi.org/10.18786/2072-0505-2018-46-6-598-608

14. Narang TK, Ahrens W, Russo MW. Post-liver transplant cholestatic hepatitis C: a systematic review of clinical and pathological findings and application of consensus criteria. Liver Transpl. 2010;16(11):1228–1235. PMID: 21031537 https://doi.org/10.1002/lt.22175

15. Ok E, Unsal A, Celik A, Zeytinoğlu A, Ersöz G, Tokat Y, et al. Clinicopathological features of rapidly progressive hepatitis C virus infection in HCV antibody negative renal transplant recipients. Nephrol Dial Transplant. 1998;13(12):3103–3107. PMID: 9870473 https://doi.org/10.1093/ndt/13.12.3103

16. Bernardin F, Stramer SL, Rehermann B, Page-Shafer K, Cooper S, Bangsberg DR, et al. High levels of subgenomic HCV plasma RNA in immunosilent infections. Virology. 2007;365(2):446– 456. PMID: 17493654 https://doi.org/10.1016/j.virol.2007.04.003

17. Kazmierczak J, Pawelczyk A, Cortes KC, Radkowski M. Seronegative hepatitis C virus infection. Arch Immunol Ther Exp (Warsz). 2014;62(2):145– 151. PMID: 24202543 https://doi.org/10.1007/s00005-013-0257-7

18. Berenguer M. Systematic review of the treatment of established recurrent hepatitis C with pegylated interferon in combination with ribavirin. J Hepatol. 2008;49(2):274–287. PMID: 18571272 https://doi.org/10.1016/j.jhep.2008.05.002

19. Wang CS, Ko HH, Yoshida EM, Marra CA, Richardson K. Interferonbased combination anti-viral therapy for hepatitis C virus after liver transplantation: a review and quantitative analysis. Am J Transplant. 2006;6(7):1586– 1599. PMID: 16827859 https://doi.org/10.1111/j.1600-6143.2006.01362.x

20. Leroy V, Dumortier J, Coilly A, Sebagh M, Fougerou-Leurent C, Radenne S, et al. Efficacy of sofosbuvir and daclatasvir in patients with fibrosing cholestatic hepatitis C after liver transplantation. Clin Gastroenterol Hepatol. 2015;13(11):1993-2001.e1–2. PMID: 26044317 https://doi.org/10.1016/j.cgh.2015.05.030

21. Forns X, Mutimer D, Manns M, Reddy KR, Everson GT, Flamm SL, et al. P0779: Ledipasvir/sofosbuvir with ribavirin for the treatment of fibrosing cholestatic hepatitis C after liver transplantation. J Hepatol. 2015;62(Suppl 2):S623. https://doi.org/10.1016/s0168-8278(15)30982-x

22. Agarwal K, Castells L, Mullhaupt B, Rosenberg WMC, McNabb B, Arterburn S, et al. Sofosbuvir/velpatasvir for 12 weeks in genotype 1-4 HCVinfected liver transplant recipients. J Hepatol. 2018;69(3):603–607. PMID: 29886154 https://doi.org/10.1016/j.jhep.2018.05.039

23. Reau N, Kwo PY, Rhee S, Brown RS Jr, Agarwal K, Angus P, et al. Glecaprevir/pibrentasvir treatment in liver or kidney transplant patients with hepatitis C virus infection. Hepatology. 2018;68(4):1298–1307. PMID: 29672891 https://doi.org/10.1002/hep.30046

24. Merli M, Rossotti R, Travi G, Ferla F, Lauterio A, Zucchetti TA, et al. Sustained virological response with 16-week glecaprevir/pibrentasvir after failure to sofosbuvir/velpatasvir in post-transplant severe HCV recurrence in HIV. Transpl Infect Dis. 2019;21(6):e13165. PMID: 31487082 https://doi.org/10.1111/tid.13165

25. Shinzato T, Kubo T, Shimizu T, Nanmoku K, Yagisawa T. Fibrosing cholestatic hepatitis in a kidney transplant recipient with hepatitis C virus. CEN Case Rep. 2019;8(2):101–105. PMID: 30604247 https://doi.org/10.1007/s13730-018-0374-6